Affordable Access

Publisher Website

A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.

Authors
  • 1
Type
Published Article
Journal
BMC Cancer
1471-2407
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Volume
8
Pages
169–169
Identifiers
DOI: 10.1186/1471-2407-8-169
PMID: 18544172
Source
Medline

Abstract

This preliminary study suggests that: an increase in EGFR copy number may be associated with cetuximab response but is a rare event in CRC, KRAS mutations are associated with low response rate but do not preclude any cetuximab-based combination efficacy and EGFR exon 13 variant (R521K) may predict for cetuximab benefit.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F